Posters
« Back
ALS Drug Discovery via High-Throughput Phenotypic Screening Using iPSC-Derived Human Motor Neurons
EP30225
Poster Title: ALS Drug Discovery via High-Throughput Phenotypic Screening Using iPSC-Derived Human Motor Neurons
Submitted on 31 May 2019
Author(s): Paul J. Guyett1*, Michael Hendrickson1, Jennifer Kouznetsova2, Wei Zheng2, Zhong-Wei Du1
Affiliations: 1BrainXell, Inc., Madison, WI, USA, 2NCATS/NIH, Rockville, MD, USA
Poster Views: 313
View poster »


Poster Information
Abstract: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease primarily affecting motor neurons. Unfortunately, there are only two drugs approved to treat the condition, neither of which increases patient survival by more than a few months. This sobering reality highlights the urgent need for new ALS therapeutic development, which has been plagued by high failure rate of drug candidates during clinical trials. This high failure rate suggests that preclinical screening strategies need to be re-evaluated. One of the markers of disease in ALS patients is the aberrantly low expression of neurofilament light chain (NFL) in motor neurons. Further, recovery of NFL to normal levels prevents hallmark phenotypic changes in ALS neurons. Therefore, we wanted to establish a clinically relevant screening platform to identify compounds that return expression of NFL to normal levels in ALS patient derived motor neurons. At BrainXell, we established new technologies to rapidly differentiate ALS patient induced pluripotent stem cells (iPSCs) into large quantities of neurons. We then used genome editing techniques to endogenously fuse NFL with a nanoluciferase (NLuc) reporter, thus enabling a high-throughput screening (HTS) system that monitors the expression levels of NFL after 72 h exposure to each compound. The assay was adapted to meet HTS requirements, including: large batch sizes, 1536-well format, minimal well-to-well variation, short-term culture, plating by automated dispenser, and low reagent volumes. Applying a quantitative HTS approach, we screened the LOPAC, NPC, and MIPE libraries (>6,000 compounds) in a dose dependent manner. Compounds that increase NFL expression by >30% (to approximately normal levels) were considered hits. From these screens we identified 80 hit compounds that are currently going through secondary validation. Preliminary data look promising. For example, two of these hits restore normal expression of NFL with no observed toxicity.Summary: At BrainXell, we established new technologies to rapidly differentiate ALS patient induced pluripotent stem cells (iPSCs) into large quantities of neurons.References: 1. Chen, H., et al. (2014). Cell Stem Cell 14(6): 796-809.
2. Kong, J. and Z. Xu (2000). Neuroscience Letters 281(1): 72-74.
Report abuse »
Questions
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters


Do patients presenting with Stroke get timely and appropriate investigations?
Mac a' Bháird K, Nawaz GD, Cameron CM, McManus J, Hunter MA

An interesting case of peripheral nerve sheath tumour presenting with acute onset progressive quadriparesis
Sumit Kumar, Prateek Luthra, Rahul Dev

Reward Modulates Local Field Potentials, Spiking Activity and Spike-Field Coherence in the Primary Motor Cortex
Junmo An, Taruna Yadav, John P Hessburg, Joseph T Francis

THERAPEUTIC EFFICACY OF OPEN VERSUS CLOSED KINETIC STRENTH TRAINING WITH BILATERAL AFO FOR THE TREATMENT OF SPASTICITY DIPLEGICS GAIT CONDITIONS -COMPARATIVE STUDY
Karthikeyan T

Accelerated Ageing in Depression: A Study of Two Cohorts
Mathew A. Harris, Laura de Nooij, Xueyi Shen, Toni-Kim Clarke, Riccardo Marioni, Simon R. Cox, Emma L. Hawkins, Mark J. Adams, Liana Romaniuk, Stephen M. Lawrie, James H. Cole, Andrew M. McIntosh and Heather C. Whalley